Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
21 Leser
Artikel bewerten:
(0)

Research and Markets - Preclinical Imaging (In-VIVO) Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are Aspect Imaging, Fujifilm & MR Solutions

DUBLIN, Nov 15, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Preclinical Imaging (In-VIVO) Market by Modality and by Reagent - Global Forecast to 2021" report to their offering.

The global preclinical imaging market is expected to reach a value of USD 910.4 Million by 2021; growing at a CAGR of 6.2% during 2016-2021.

A number of factors such as technological advancements in the field of molecular imaging, increasing market demand for non-invasive small animal imaging techniques, and growing number of public-private initiatives and funding to support preclinical researches are propelling the growth of the global preclinical imaging market. However, factors such as strict regulatory framework that governs preclinical researches, and significant installation and operational costs associated with preclinical imaging modalities are some of the major factors restraining the growth of this market. In addition to this, technological & procedural limitations associated with standalone systems is a major challenge for players in this market.

In 2016, the global preclinical imaging market is expected to be dominated by North America. A number of factors such as robust R&D infrastructure for life science researches, fast adoption of novel molecular imaging technologies, significant presence of pharmaceutical and biotechnology companies, and increasing preference of end users for multimodality systems are driving the growth of the preclinical imaging market in the North American region.

The Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. This is primarily due to the continuous government support for pharmaceutical and biotechnology R&D, increasing public-private investments to support radioisotope production, rising number of translational research activities, and evolving regulatory scenario across major Asian countries.

Companies Mentioned:

  • Aspect Imaging Ltd.
  • Bruker Corporation
  • Fujifilm Holdings Corporation
  • Li-Cor Biosciences
  • MR Solutions Ltd.
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotec GmbH
  • Perkinelmer, Inc.
  • Trifoil Imaging

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Preclinical Imaging Market Overview

6 Industry Insights

7 Global Preclinical Imaging Market, By Modality

8 Global Preclinical Imaging Market, By Reagent

9 Preclinical Imaging Market, By Region

10 Competitive Landscape

11 Company Profiles

For more information about this report visit http://www.researchandmarkets.com/research/9h48bq/preclinical

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.